News | CEBINA

top of page

Latest News

04 September 2025

Phase 2 clinical trial with an anti-allergy nasal spray confirms CEBINA's drug repurposing discovery research findings on Azelastine as a new antiviral approach.

23 July 2025

CEBINA and Eveliqure announce dosing of first participants in a Phase 2b study of the ShigETEC vaccine in Shigellosis.

Get in touch

We're here to collaborate and innovate -

contact us to start the conversation

+43 (0)1 9092208

11 December 2024- Launch of TAG Therapeutics
17 September 2024- CEBINA and Charles River Laboratories announce strategic collaboration
28 February 2024- Launch of DanubeNeuro, neurdegeneration accelerator program
18 December 2023 - Eveliqure initiates clinical safety and immunogenicity trials of its vaccine candidate against Shigellosis and ETEC in endemic populations in Bangladesh
12 September 2023 - Danube Labs: Call for Proposals - September 2023
02 May 2023 - CEBINA Announces Positive Results of a Phase 2 Clinical Study with COVID-19 patients and Azelastine Nasal Spray Published in a Peer-Reviewed Scientific Journal
07 March 2023 - Danube Labs: Call for Proposals - April 2023
04 July 2022 - CEBINA publishes data demonstrating the anti-histamine azelastine inhibits infection by major variants of SARS-CoV-2
19 April 2022 - Danube Labs: Call for Proposals
23 February 2022 - Eveliqure announces the publication of positive Phase I clinical data for its vaccine candidate against Shigellosis and ETEC
03 February 2022 - Azelastine - the active drug in anti-allergy nasal sprays demonstrated to have potent anti-viral effect on the Omicron variant of SARS-CoV-2
10 December 2021 - CEBINA reports broad anti-viral potency of azelastine, an antihistamine widely available as a nasal spray, has potential for use against influenza and RSV infections in addition to SARS-CoV-2 and its variants of concern including the Omicron variant
17 August 2021 - Widely available anti-allergy azelastine nasal spray poised to revolutionize COVID-19 management
14 June 2021 - CEBINA announces the launch of Danube Labs, a partnership with Evotec to develop cutting edge biotechnology projects sourced from Central and Eastern European Universities and Research Institutions
04 May 2021 - CEBINA reports potency of azelastine against emerging dominant variants of SARS-CoV-2 in laboratory testing
17 February 2021 - URSAPHARM Arzneimittel and CEBINA announce partnership to repurpose the antihistamine azelastine to combat COVID-19
19 November 2020 - Eveliqure announces the publication of key preclinical data for its clinical stage vaccine candidate against Shigellosis and ETEC
24 September 2020 - Eveliqure announces the initiation of a Phase 1 clinical study of its combined Shigella and ETEC vaccine candidate
17 September 2020 - CEBINA reports positive findings on the potency of azelastine, a widely used anti-histamine, as anti-COVID-19 approach
09 September 2020 - Eveliqure announces the award of a NIAID contract to finance Phase 2 clinical studies of its combined Shigella and ETEC vaccine candidate
9 July 2020 - CEBINA identifies a common antihistamine nasal spray as a potential anti-COVID-19 approach
30 June 2020 - Eveliqure secures further private investment to support development of its combined Shigella and ETEC vaccine candidate
4 June 2020 - CEBINA secures seed funding for its unique extended spectrum Coronavirus vaccine
2 June 2020 - Eveliqure Biotechnologies announces regulatory approval to initiate first clinical trial of its ShigETEC vaccine candidate Biotechnologies
20 April 2020 - Calyxha Biotechnologies announces grant of a European Patent on neurodegenerative diseases
17 April 2020 - CEBINA today announces the initiation of several collaborative projects that address the global health crisis caused by the pandemic spread of the SARS-CoV-2 virus
4 March 2020 - Calyxha Biotechnologies announces new financing to support pre-clinical development of its therapeutic lead candidate, CAL-X
5 November 2019 - Eveliqure Biotechnologies GmbH announces a grant from the Wellcome Trust to support their effort to develop a Shigella-ETEC combination vaccine for travelers and children in resource poor countries

Previous News

Publications

bottom of page